ZA200504109B - Escitalopram hydrobromide and a method for the preparation thereof - Google Patents
Escitalopram hydrobromide and a method for the preparation thereof Download PDFInfo
- Publication number
- ZA200504109B ZA200504109B ZA200504109A ZA200504109A ZA200504109B ZA 200504109 B ZA200504109 B ZA 200504109B ZA 200504109 A ZA200504109 A ZA 200504109A ZA 200504109 A ZA200504109 A ZA 200504109A ZA 200504109 B ZA200504109 B ZA 200504109B
- Authority
- ZA
- South Africa
- Prior art keywords
- disorder
- disorders
- escitalopram
- escitalopram hydrobromide
- hydrobromide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200202005 | 2002-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200504109B true ZA200504109B (en) | 2006-08-30 |
Family
ID=32668635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200504109A ZA200504109B (en) | 2002-12-23 | 2005-05-20 | Escitalopram hydrobromide and a method for the preparation thereof |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20040167209A1 (https=) |
| EP (1) | EP1578738B1 (https=) |
| JP (2) | JP4658613B2 (https=) |
| KR (1) | KR20050086933A (https=) |
| CN (1) | CN100349885C (https=) |
| AR (1) | AR042652A1 (https=) |
| AT (1) | ATE388947T1 (https=) |
| AU (1) | AU2003287919B2 (https=) |
| BR (1) | BR0317623A (https=) |
| CA (1) | CA2511142A1 (https=) |
| CY (1) | CY1107451T1 (https=) |
| DE (1) | DE60319739T2 (https=) |
| DK (1) | DK1578738T3 (https=) |
| EA (1) | EA013116B1 (https=) |
| EG (1) | EG24729A (https=) |
| ES (1) | ES2298595T3 (https=) |
| IL (1) | IL169125A0 (https=) |
| IS (1) | IS2654B (https=) |
| ME (1) | MEP5808A (https=) |
| MX (1) | MXPA05005772A (https=) |
| MY (1) | MY135468A (https=) |
| NO (1) | NO20053595L (https=) |
| NZ (1) | NZ540281A (https=) |
| PE (1) | PE20040924A1 (https=) |
| PL (1) | PL378275A1 (https=) |
| PT (1) | PT1578738E (https=) |
| RS (1) | RS51092B (https=) |
| TW (1) | TW200501943A (https=) |
| UA (1) | UA80170C2 (https=) |
| UY (1) | UY28148A1 (https=) |
| WO (1) | WO2004056791A1 (https=) |
| ZA (1) | ZA200504109B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA80170C2 (en) * | 2002-12-23 | 2007-08-27 | Lundbeck & Co As H | Escitalopram hydrobromide |
| US20050137255A1 (en) * | 2002-12-23 | 2005-06-23 | H. Lundbeck A/S | Crystalline escitalopram hydrobromide and methods for preparing the same |
| AU2005218713B2 (en) * | 2004-03-05 | 2009-11-19 | H. Lundbeck A/S | Crystalline composition containing escitalopram oxalate |
| TWI358407B (en) | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
| US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| AU2006304889A1 (en) * | 2005-10-14 | 2007-04-26 | H. Lundbeck A/S | Stable pharmaceutical formulations containing escitalopram and bupropion |
| EP1954257A4 (en) * | 2005-10-14 | 2009-05-20 | Lundbeck & Co As H | METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| ES2687756T3 (es) * | 2006-07-11 | 2018-10-29 | Mitsubishi Tanabe Pharma Corporation | Sal de un compuesto de morfolina |
| WO2008059514A2 (en) * | 2006-07-31 | 2008-05-22 | Cadila Healthcare Limited | Process for preparing escitalopram |
| FR3006594A1 (fr) * | 2013-06-11 | 2014-12-12 | Sorin Crm Sas | Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire |
| CN108976188B (zh) * | 2017-06-05 | 2022-12-06 | 上海奥博生物医药股份有限公司 | 一种艾司西酞普兰双羟萘酸盐新的制备方法 |
| RU2020111694A (ru) * | 2017-10-09 | 2021-11-12 | Тева Фармасьютикал Индастриз Лтд. | Новые соли и твердые формы эсциталопрама |
| US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US34712A (en) * | 1862-03-18 | James h | ||
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| CA2291134C (en) * | 1998-10-20 | 2006-05-23 | H. Lundbeck A/S | Method for the preparation of citalopram |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| TR200401456T1 (tr) * | 1999-10-25 | 2005-04-21 | H. Lundbeck A/S | Sitalopram hazırlanması için yöntem. |
| US6977306B2 (en) * | 2000-05-02 | 2005-12-20 | Sumitomo Chemical Company, Limited | Citalopram hydrobromide crystal and method for crystallization thereof |
| JP2002020379A (ja) * | 2000-05-02 | 2002-01-23 | Sumika Fine Chemicals Co Ltd | シタロプラム臭化水素酸塩の結晶およびその結晶化方法 |
| IES20010693A2 (en) * | 2000-08-10 | 2002-07-10 | Lundbeck & Co As H | Pharmaceutical composition containing citalopram |
| BR0115907B1 (pt) * | 2000-12-04 | 2011-10-04 | processo para o tratamento prévio de óleos crus e graxas cruas para uma subsequente transesterificação alcalina com álcoois primários e/ou secundários e processo para a produção de ésteres de ácido graxo de álcoois primários e/ou secundários a partir de óleos crus ou graxas cruas que contém ácidos graxos livres e substáncias mucilaginosas ou a partir de óleos velhos carregados com ácidos graxos livres da indústria alimentìcia. | |
| EA200301195A1 (ru) * | 2001-05-01 | 2004-04-29 | Х. Лундбекк А/С | Применение энантиомерно чистого эсциталопрама |
| AR034612A1 (es) * | 2001-06-25 | 2004-03-03 | Lundbeck & Co As H | Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram |
| UA80170C2 (en) * | 2002-12-23 | 2007-08-27 | Lundbeck & Co As H | Escitalopram hydrobromide |
| US20050174782A1 (en) * | 2003-03-25 | 2005-08-11 | Chapman Leonard T. | Flashlight |
-
2003
- 2003-12-18 UA UAA200506077A patent/UA80170C2/uk unknown
- 2003-12-18 KR KR1020057011704A patent/KR20050086933A/ko not_active Ceased
- 2003-12-18 JP JP2004561083A patent/JP4658613B2/ja not_active Expired - Lifetime
- 2003-12-18 DE DE60319739T patent/DE60319739T2/de not_active Expired - Lifetime
- 2003-12-18 DK DK03779759T patent/DK1578738T3/da active
- 2003-12-18 ME MEP-58/08A patent/MEP5808A/xx unknown
- 2003-12-18 AU AU2003287919A patent/AU2003287919B2/en not_active Ceased
- 2003-12-18 NZ NZ540281A patent/NZ540281A/en not_active Application Discontinuation
- 2003-12-18 PL PL378275A patent/PL378275A1/pl not_active Application Discontinuation
- 2003-12-18 RS YUP-2005/0487A patent/RS51092B/sr unknown
- 2003-12-18 WO PCT/DK2003/000902 patent/WO2004056791A1/en not_active Ceased
- 2003-12-18 CN CNB2003801063775A patent/CN100349885C/zh not_active Expired - Fee Related
- 2003-12-18 AT AT03779759T patent/ATE388947T1/de not_active IP Right Cessation
- 2003-12-18 EA EA200501046A patent/EA013116B1/ru not_active IP Right Cessation
- 2003-12-18 EP EP03779759A patent/EP1578738B1/en not_active Expired - Lifetime
- 2003-12-18 ES ES03779759T patent/ES2298595T3/es not_active Expired - Lifetime
- 2003-12-18 BR BR0317623-1A patent/BR0317623A/pt not_active IP Right Cessation
- 2003-12-18 CA CA002511142A patent/CA2511142A1/en not_active Abandoned
- 2003-12-18 MX MXPA05005772A patent/MXPA05005772A/es active IP Right Grant
- 2003-12-18 PT PT03779759T patent/PT1578738E/pt unknown
- 2003-12-22 AR ARP030104777A patent/AR042652A1/es unknown
- 2003-12-22 MY MYPI20034949A patent/MY135468A/en unknown
- 2003-12-22 TW TW092136380A patent/TW200501943A/zh unknown
- 2003-12-23 US US10/746,913 patent/US20040167209A1/en not_active Abandoned
- 2003-12-23 UY UY28148A patent/UY28148A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 PE PE2004000013A patent/PE20040924A1/es not_active Application Discontinuation
-
2005
- 2005-05-17 IS IS7848A patent/IS2654B/is unknown
- 2005-05-20 ZA ZA200504109A patent/ZA200504109B/en unknown
- 2005-06-09 IL IL169125A patent/IL169125A0/en unknown
- 2005-06-22 EG EGNA2005000345 patent/EG24729A/xx active
- 2005-07-25 NO NO20053595A patent/NO20053595L/no not_active Application Discontinuation
-
2008
- 2008-05-02 CY CY20081100470T patent/CY1107451T1/el unknown
-
2010
- 2010-10-20 JP JP2010235287A patent/JP2011037893A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011037893A (ja) | 臭化水素酸エスシタロプラム(escitalopramhydrobromide)およびその製造方法 | |
| AU2001100399A4 (en) | Process for the preparation of pure citalopram | |
| BR9917368B1 (pt) | mÉtodo para preparaÇço de citalopram. | |
| IL147226A (en) | Process for the preparation of pure citalopram | |
| IES20010760A2 (en) | Method for the preparation of citalopram | |
| NZ521200A (en) | Method for the preparation of citalopram | |
| US8288568B2 (en) | Process for the preparation of escitalopram | |
| JPH08510477A (ja) | 新規なn−ベンゾイルメチル−ピペリジン類 | |
| HK1087708B (en) | Escitalopram hydrobromide and a method for the preparation thereof | |
| US20050137255A1 (en) | Crystalline escitalopram hydrobromide and methods for preparing the same | |
| EP1485367B1 (en) | Purified citalopram salts | |
| JP2017019727A (ja) | デュロキセチン塩基及びデュロキセチン塩酸塩の製造方法 | |
| KR20140020981A (ko) | 메실화에 의한 드로네다론의 제조방법 |